ROSWELL PARK CANCER INSTITUTE CORP
Optimizing Dual-Targeted and Dual-Armored CAR T Cells for Small Cell LungCancer
Optimizing Dual-Targeted and Dual-Armored CAR T Cells for Small Cell LungCancer is a funding opportunity from ROSWELL PARK CANCER INSTITUTE CORP, up to 696801, closing March 31, 2027.
Mar 31, 2027
(243d left)Overview
ABSTRACT A patient's own T cells can be modified using gene therapy technology to express receptors, termed chimeric antigen receptors or CARs, which allow these immune T cells to recognize proteins on the tumor cell surface, and in turn allow these CAR modified T cells to recognize and kill the patient's own tumor…